glp-1 success Beyond the Shot: Why Depends on the Plan Behind the Prescription Retention, Renewal, Results: Noom's GLP‑1

Similarly, a recent phase 2 trial of Lixisenatide in early PD showed a stable motor score over 12 months ( 0.04 points), contrasting with a decline in the placebo group (+ 3.04 points), resulting in an adjusted mean difference of 3.08 points ( p = 0.007)

Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, et al

10.1074/jbc.M211899200 J

More information on vitamin B12

Large meta-analyses and pooled data from randomized controlled trials demonstrate that GLP-1 receptor agonists do not increase the risk of depression, anxiety, suicidality, or other serious psychiatric adverse events compared to placebo

Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia